Evaluating the safety and tolerability of FB418 in healthy adults and elderly

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety and tolerability of FB418 through single and multiple ascending oral doses in healthy adult and elderly subjects. The first part focuses on single doses, evaluating pharmacokinetics and the impact of food on drug absorption. The second part examines the effects of multiple doses on safety and pharmacokinetics. The study is designed to gather essential data on how FB418 behaves in the body and its overall safety profile.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Healthy, adult, male 19 55 years of age, inclusive, at the screening.
2. For elderly subjects(Part A Cohort 5 only), healthy, elderly, male or female (of non childbearing potential only) over 60 years of age, inclusive, at screening.
3. In the case of the elderly(Part A Cohort 5 only), they have a history of mild disease, but can participate if the researcher judges that they can stop taking the drug at least 2 weeks before the expected first dose or before the half-life is 5 times or more)
4. The continuous non smoker who have not used nicotine containing products for at least 3 months prior to (the first) dosing and throughout the study are based on subjective self reporting.
5. Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2 at the screening.
6. Medically healthy with no clinically significant medical history, physical examination, simplified neurological examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.
7. In Cohort 5, A female subject must be of non childbearing potential

Key Exclusion Criteria:

1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
2. History or presence of a clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
4. Is at suicidal risk in the opinion of the PI as per the following criteria:

   1. Any suicide attempts within 12 months prior to screening or any suicidal intent, including a plan, within 3 months prior to screening.
   2. C-SSRS answer of "YES" on suicidal ideation within 3 months prior to screening.
5. History or presence of alcoholism or drug abuse within the past 2 years prior to (the first) dosing.
6. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
7. History of seizures (childhood febrile seizures are excepted).
8. Positive urine drug or alcohol results at screening or check in.
9. Has an abnormal screening ECG indicating a second- or third- degree AV block, or one or more of the following: QRS \> 120 msec, QTcF \> 450 msec for males and \> 460 msec for females, PR interval \> 220 msec. Any rhythm other than normal sinus rhythm, which is interpreted by the PI or designee to be clinically significant at screening or check-in.
10. Has any medical or surgical condition in which lumbar puncture is contraindicated in the opinion of the PI.

Where it's running

• Seoul National University
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: 1STBIO information team
• Email: info@1stbio.com
• Phone: +82-31-895-4677

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early detection of respiratory impairment in ALS using breathing, MRI, and blood markers

  This study tests whether breathing patterns, MRI changes in the brainstem and spinal cord, and blood markers can reveal early ALS signs, especially in people with genetic risk or early symptoms.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07844590

• Plasmapheresis for ALS with anti-NRIP autoantibody

  This study tests whether a few plasmapheresis sessions can help people with ALS who have anti-NRIP autoantibody by keeping the antibody levels low.

  Recruiting National Taiwan University Hospital · Taipei City, Taipei · NCT07726563

• Implanted brain interface to let people with severe paralysis control assistive devices

  It will try an implanted brain interface that records and stimulates brain signals so adults with severe paralysis can control assistive devices and receive sensory feedback.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07521930

• Do video recordings of multidisciplinary clinics help ALS patients and caregivers?

  This study tests whether providing a video recording of ALS multidisciplinary clinic visits, in addition to written notes, helps patients and their caregivers manage information and feel better about care.

  Recruiting Trustees of Dartmouth College · Scottsdale, Arizona and 6 other locations · NCT07454733

• Measuring Hsp90 levels in the human brain

  This trial tests whether a PET tracer called [11C]HSP990 can measure Hsp90 levels in the brains of healthy adults and people with Parkinson's disease, Alzheimer's disease, or ALS.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven, Vlaam-Brabant · NCT07380204

• NB-4746 in people with ALS

  This trial tests NB-4746 against placebo to see if it is safe and may help people with ALS.

  Recruiting at 12 sites Phase 1/2 Nura Bio · Concord, New South Wales and 11 other locations · NCT07369076

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.